These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 28875476)

  • 1. Treatment of primary membranous nephropathy: where are we now?
    Angioi A; Lepori N; López AC; Sethi S; Fervenza FC; Pani A
    J Nephrol; 2018 Aug; 31(4):489-502. PubMed ID: 28875476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
    Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of idiopathic membranous nephropathy.
    Waldman M; Austin HA
    J Am Soc Nephrol; 2012 Oct; 23(10):1617-30. PubMed ID: 22859855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
    Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
    Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
    Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
    Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.
    Glassock RJ
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1341-3. PubMed ID: 25035274
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
    Guerry MJ; Vanhille P; Ronco P; Debiec H
    Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
    [No Abstract]   [Full Text] [Related]  

  • 10. Membranous nephropathy.
    Mathieson PW
    Clin Med (Lond); 2012 Oct; 12(5):461-6. PubMed ID: 23101149
    [No Abstract]   [Full Text] [Related]  

  • 11. Membranous Nephropathy: Updates on Management.
    Bharati J; Waguespack DR; Beck LH
    Adv Kidney Dis Health; 2024 Jul; 31(4):299-308. PubMed ID: 39084755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of autoantibodies in primary membranous nephropathy and their clinical significance.
    Stahl RA; Reinhard L; Hoxha E
    Expert Rev Clin Immunol; 2019 Feb; 15(2):165-175. PubMed ID: 30433832
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
    Brenchley PE
    J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
    [No Abstract]   [Full Text] [Related]  

  • 14. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
    Netti GS; Ranieri E
    G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of membranous nephropathy: time for a paradigm shift.
    Ruggenenti P; Fervenza FC; Remuzzi G
    Nat Rev Nephrol; 2017 Sep; 13(9):563-579. PubMed ID: 28669992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China.
    Wu L; Lai J; Ling Y; Weng Y; Zhou S; Wu S; Jiang S; Ding X; Jin X; Yu K; Chen Y
    Med Sci Monit; 2021 Feb; 27():e930097. PubMed ID: 33550324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
    Ishiwatari A; Wakai S; Shirakawa H; Honda K
    Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
    Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
    Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of Patients With Refractory PLA
    Klomjit N; Fervenza FC; Zand L
    Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.